Drug intelligence / Profile preview

Hipra RSV vaccine

Development stage: Preclinical
Lead developer: Hipra
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Hipra RSV vaccine is a preventive vaccine candidate currently in preclinical development for the prevention of Respiratory Syncytial Virus (RSV) infection and its associated clinical manifestations, including bronchiolitis and pneumonia. Developed by Hipra in collaboration with CURAPATH, Biotechvana S.L., and Nostrum Biodiscovery, the vaccine is designed to induce protective immunity against the virus. While specific details regarding the antigen or platform have not been publicly disclosed, the project leverages Hipra's expertise in vaccine development to address a significant cause of lower respiratory tract infections in infants and the elderly.

Other names: RSV vaccine

Beyond the preview

Go deeper on Hipra RSV vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hipra RSV vaccine.

Explore the full profile